Aurinia Pharmaceuticals ( (AUPH) ) just unveiled an announcement.
Aurinia Pharmaceuticals reported a significant increase in financial performance for the fourth quarter and full year of 2024, with total revenue rising by 33% and 34% respectively compared to 2023. The company’s net product sales of LUPKYNIS saw a notable growth, contributing to a positive net income for both the quarter and the year, marking a substantial turnaround from the previous year’s losses. This financial improvement underscores Aurinia’s strengthened position in the market and its successful commercialization efforts.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for autoimmune diseases. Its primary product, LUPKYNIS, is the first FDA-approved oral therapy for treating adult patients with active lupus nephritis.
YTD Price Performance: -9.35%
Average Trading Volume: 1,312,832
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.14B
For detailed information about AUPH stock, go to TipRanks’ Stock Analysis page.